obesity drug news today glp-1 oct 27 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ GLP-1 agonists and changes in

GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction

This and other trials have shown improvements in patients lipid profiles with the most pronounced impact on reduction of triglycerides

This review examines the biological mechanisms underlying GLP-1 RA therapy in MASLD/MASH, analyzes the mechanistic distinctions between mono-, dual-, and triple agonists, and synthesizes current clinical evidence supporting their utilization in individuals with this condition.

This review summarizes current evidence on the nutritional implications of GLP1-based pharmacotherapy in adults with obesity, including common gastrointestinal adverse events, reduced energy intake, potential macro and micronutrient inadequacies, and risks of lean mass loss

One key may lie in enhancing your bodys natural production of GLP-1 (Glucagon-like Peptide-1) a hormone secreted by the small intestine after eating

Methods A retrospective study was conducted using electronic medical records from 2014 to 2019 for adults with T2D at the Valencia Clnico-Malvarrosa Department of Health (Valencia, Spain)